feedzop-word-mark-logo
searchLogin
Feedzop
homeFor YouIndiaIndia
You
bookmarksYour BookmarkshashtagYour Topics
Trending
trending

Faf du Plessis retires from IPL

trending

HDFC Bank stock live updates

trending

Paytm share price rallies

trending

IPL auction: 1355 players register

trending

Devdutt Padikkal scores century

trending

Hardik Pandya returns to cricket

trending

Bangladesh wins T20I series

trending

Sarfaraz Khan slams century

trending

AIIMS: effects of sleep deprivation

Terms of UsePrivacy PolicyAboutJobsPartner With Us

© 2025 Advergame Technologies Pvt. Ltd. ("ATPL"). Gamezop ® & Quizzop ® are registered trademarks of ATPL.

Gamezop is a plug-and-play gaming platform that any app or website can integrate to bring casual gaming for its users. Gamezop also operates Quizzop, a quizzing platform, that digital products can add as a trivia section.

Over 5,000 products from more than 70 countries have integrated Gamezop and Quizzop. These include Amazon, Samsung Internet, Snap, Tata Play, AccuWeather, Paytm, Gulf News, and Branch.

Games and trivia increase user engagement significantly within all kinds of apps and websites, besides opening a new stream of advertising revenue. Gamezop and Quizzop take 30 minutes to integrate and can be used for free: both by the products integrating them and end users

Increase ad revenue and engagement on your app / website with games, quizzes, astrology, and cricket content. Visit: business.gamezop.com

Property Code: 5571

Home / Health / One-Shot Cholesterol Cure Hailed as 'Game-Changer'

One-Shot Cholesterol Cure Hailed as 'Game-Changer'

1 Dec

•

Summary

  • A single drug infusion may eliminate high cholesterol for life.
  • Experimental treatment targets and switches off a key gene.
  • This new therapy could offer an alternative to daily statins.
One-Shot Cholesterol Cure Hailed as 'Game-Changer'

A revolutionary one-off drug injection, currently known as VERVE-102, is showing remarkable potential to permanently lower high cholesterol levels. This pioneering gene therapy targets and deactivates a specific gene that drives the production of LDL, commonly referred to as 'bad' cholesterol. Preliminary studies involving a small group of patients demonstrated a substantial decrease in LDL levels following a single infusion.

While large-scale trials are necessary to confirm its safety and efficacy, experts are optimistic about VERVE-102's implications. It could provide a crucial alternative for individuals unresponsive to existing treatments or seeking a more convenient, non-daily regimen than statins. Approximately half of UK adults contend with high cholesterol, a condition linked to increased risks of heart attacks and strokes.

Currently, statins are the primary treatment, effectively lowering LDL for many. However, side effects lead some patients to discontinue use. VERVE-102 offers a novel approach, aiming to genetically 'switch off' the cholesterol-raising mechanism. Despite the promise, concerns about the potential cost of gene-editing therapies and the need for long-term safety data remain.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
VERVE-102 is an experimental drug showing promise for lifelong cholesterol reduction with one shot, but larger trials are needed for confirmation.
VERVE-102 targets and genetically switches off a gene responsible for producing 'bad' LDL cholesterol in the liver.
Besides statins, options include PCSK9 inhibitors (injections) and the experimental one-off gene therapy VERVE-102.

Read more news on

Healthside-arrow

You may also like

B12 Tablets: A Silent Deficiency Deceiver?

6 hours ago • 2 reads

article image

Unapproved Peptide Injections: Viral Hype vs. Real Risks

28 Nov • 2 reads

article image

Black Diamond Group: Analysts Eye C$17 Target

29 Nov • 6 reads

article image

New Super-Jabs Promise 25% Weight Loss

25 Nov • 36 reads

article image

Novo Nordisk Alzheimer's Trial Fails to Slow Decline

24 Nov • 37 reads

article image